Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 2.7128
-10.2 %
$ 20.8 M
Market Cap
-5.08
P/E
1. INTRINSIC VALUE
Balance Sheet
NEXGEL, Inc.
| Current Assets | 5.11 M |
| Cash & Short-Term Investments | 1.81 M |
| Receivables | 933 K |
| Other Current Assets | 2.37 M |
| Non-Current Assets | 5.87 M |
| Long-Term Investments | 0 |
| PP&E | 3.84 M |
| Other Non-Current Assets | 2.03 M |
| Current Liabilities | 2.47 M |
| Accounts Payable | 761 K |
| Short-Term Debt | 296 K |
| Other Current Liabilities | 1.41 M |
| Non-Current Liabilities | 2.43 M |
| Long-Term Debt | 2.43 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
NEXGEL, Inc.
| Revenue | 8.69 M |
| Cost Of Revenue | 5.94 M |
| Gross Profit | 2.75 M |
| Operating Expenses | 6.3 M |
| Operating Income | -3.55 M |
| Other Expenses | -273 K |
| Net Income | -3.28 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NEXGEL, Inc.
| Net Income | -3.28 M |
| Depreciation & Amortization | 478 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 367 K |
| Change in Working Capital | -1.17 M |
| Others | -881 K |
| Free Cash Flow | -3.87 M |
Wall Street Analysts Price Targets
NEXGEL, Inc.
NXGL has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
NXGL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
NEXGEL, Inc.
Sold
0-3 MONTHS
65.5 K USD 2
3-6 MONTHS
39.9 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
108 K USD 6
3-6 MONTHS
125 K USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today.
seekingalpha.com
- 1 month ago
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
globenewswire.com
- 1 month ago
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.
globenewswire.com
- 1 month ago
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Webull Consumer Virtual Webinar on February 18, 2025.
globenewswire.com
- 2 months ago
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.
globenewswire.com
- 3 months ago
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Michael Gustitus - One Pride George Marema - Pareto Adventures Operator Good afternoon, ladies and gentlemen. Welcome to NEXGEL's Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
- 5 months ago
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing
globenewswire.com
- 5 months ago
NEXGEL Announces $2,000,000 Registered Direct Offering
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance.
globenewswire.com
- 5 months ago
NEXGEL to Participate in Upcoming October Investor Conferences
LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences.
globenewswire.com
- 6 months ago
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.
globenewswire.com
- 6 months ago
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer, President and Director Adam Drapczuk - Chief Financial Officer Conference Call Participants William Odenthal - COVA Capital Partners Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.
seekingalpha.com
- 8 months ago
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively.
globenewswire.com
- 8 months ago
8. Profile
Summary
NEXGEL, Inc. NXGL
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 20.8 M
Dividend Yield
0.00%
Description
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Contact
2150 Cabot Boulevard West, Langhorne, PA, 19047
https://nexgel.com
IPO
Date
Dec. 22, 2021
Employees
19
Officers
Mr. Joseph F. McGuire
Chief Financial Officer
Mr. Adam R. Levy
Chief Executive Officer, President & Director
Mr. Gregory Robb
Vice President of Operations